Analyst Ratings For NASDAQ:BCLI – Brainstorm Cell Therapeutics (NASDAQ:BCLI)
Today, HC Wainwright initiated coverage on NASDAQ:BCLI – Brainstorm Cell Therapeutics (NASDAQ:BCLI) with a Buy with a price target of $11.00.
Some recent analyst ratings include
- 5/15/2018-HC Wainwright initiated coverage with a Buy rating.
Recent Insider Trading Activity For NASDAQ:BCLI – Brainstorm Cell Therapeutics (NASDAQ:BCLI)
NASDAQ:BCLI – Brainstorm Cell Therapeutics (NASDAQ:BCLI) has insider ownership of 24.70% and institutional ownership of 9.56%.
- On 3/15/2018 June Sherie Almenoff, Director, bought 5,700 with an average share price of $3.50 per share and the total transaction amounting to $19,950.00.
- On 3/15/2018 Ralph Dr. Kern, COO, bought 5,000 with an average share price of $3.60 per share and the total transaction amounting to $18,000.00.
- On 8/31/2017 Irit Arbel, Director, bought 2,500 with an average share price of $4.26 per share and the total transaction amounting to $10,650.00.
- On 8/23/2017 Uri Yablonka, EVP, bought 2,000 with an average share price of $3.98 per share and the total transaction amounting to $7,960.00.
- On 12/16/2015 Robert G L Shorr, Director, sold 10,800 with an average share price of $2.71 per share and the total transaction amounting to $29,268.00.
- On 12/15/2015 Malcolm S. Taub, Director, sold 41,742 with an average share price of $2.60 per share and the total transaction amounting to $108,529.20.
- On 12/11/2015 Malcolm S. Taub, Director, sold 13,480 with an average share price of $2.73 per share and the total transaction amounting to $36,800.40.
Recent Trading Activity for NASDAQ:BCLI – Brainstorm Cell Therapeutics (NASDAQ:BCLI)
Shares of NASDAQ:BCLI – Brainstorm Cell Therapeutics closed the previous trading session at 3.92 up +0.14 3.70% with 3.799999952316284 shares trading hands.